Literature DB >> 7989592

Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element.

D J Rozansky1, H Wu, K Tang, R J Parmer, D T O'Connor.   

Abstract

Glucocorticoids regulate catecholamine biosynthesis and storage at several sites. Chromogranin A, an abundant protein complexed with catecholamines in secretory vesicles of chromaffin cells and sympathetic axons, is also augmented by glucocorticoids. This study reports isolation of the rat chromogranin A promoter to elucidate transcriptional regulation of chromogranin A biosynthesis by glucocorticoids in neuroendocrine cells. Endogenous chromogranin A gene expression was activated up to 3.5-fold in chromaffin cells by glucocorticoid, in time-dependent fashion. Inhibition of new protein synthesis by cycloheximide did not alter the rise in chromogranin A mRNA, suggesting that glucocorticoids directly activate the chromogranin A promoter; nuclear runoff assays confirmed a 3.3-fold increased rate of initiation of new chromogranin A transcripts after glucocorticoid. Transfected rat chromogranin A promoter/luciferase reporter constructs were activated 2.6-3.1-fold by glucocorticoid, and selective agonist/antagonist studies determined that dexamethasone effects were mediated by glucocorticoid receptors. Both rat and mouse chromogranin A promoter/luciferase reporter constructs were activated by glucocorticoid. A series of promoter deletions narrowed the region of glucocorticoid action to a 93-bp section of the promoter, from position -526 to -619 bp upstream of the cap site. A 15-bp sequence ([-583 bp] 5'-ACATGAGTGTGTCCT-3' [-597 bp]) within this region showed partial homology to a glucocorticoid response element (GRE; half-site in italics) consensus sequence, and several lines of experimental evidence confirmed its function as a GRE: (a) site-directed mutation of this GRE prevented glucocorticoid activation of a chromogranin A promoter/reporter; (b) transfer of this GRE to a heterologous (thymidine kinase) promoter/reporter conferred activation by glucocorticoid, in copy number-dependent and orientation-independent fashion; and (c) electrophoretic gel mobility shifts demonstrated binding of this GRE by ligand-activated glucocorticoid receptor, though at 2.75-fold lower affinity than the glucocorticoid receptor interaction with a consensus GRE. The rat chromogranin A GRE showed functional and structural similarities to GREs in other genes proportionally regulated by glucocorticoids. We conclude that a discrete domain of the chromogranin A promoter is both necessary and sufficient to confer glucocorticoid regulation onto the gene, and that the activity of this region also explains the degree of activation of the endogenous gene by glucocorticoid.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989592      PMCID: PMC330065          DOI: 10.1172/JCI117601

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA.

Authors:  B F Luisi; W X Xu; Z Otwinowski; L P Freedman; K R Yamamoto; P B Sigler
Journal:  Nature       Date:  1991-08-08       Impact factor: 49.962

Review 2.  The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications.

Authors:  E E Baulieu
Journal:  Endocrinol Metab Clin North Am       Date:  1991-12       Impact factor: 4.741

3.  Dexamethasone and calcium interact in the regulation of parathormone and chromogranin-A secretion and messenger ribonucleic acid levels in parathyroid cells.

Authors:  J X Zhang; B H Fasciotto; D V Cohn
Journal:  Endocrinology       Date:  1993-07       Impact factor: 4.736

4.  DNA binding analysis of glucocorticoid receptor specificity mutants.

Authors:  I Alroy; L P Freedman
Journal:  Nucleic Acids Res       Date:  1992-03-11       Impact factor: 16.971

5.  The bovine chromogranin A gene: structural basis for hormone regulation and generation of biologically active peptides.

Authors:  A L Iacangelo; M Grimes; L E Eiden
Journal:  Mol Endocrinol       Date:  1991-11

6.  Molecular cloning and regional distribution of rat brain cyclophilin.

Authors:  R P Lad; M A Smith; D C Hilt
Journal:  Brain Res Mol Brain Res       Date:  1991-02

7.  Chromogranin A: posttranslational modifications in secretory granules.

Authors:  J A Barbosa; B M Gill; M A Takiyyuddin; D T O'Connor
Journal:  Endocrinology       Date:  1991-01       Impact factor: 4.736

8.  Calcium and catecholamine interactions with adrenal chromogranins. Comparison of driving forces in binding and aggregation.

Authors:  J S Videen; M S Mezger; Y M Chang; D T O'Connor
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

9.  Distal cis-acting promoter sequences mediate glucocorticoid stimulation of cardiac atrial natriuretic factor gene transcription.

Authors:  S Argentin; Y L Sun; I Lihrmann; T J Schmidt; J Drouin; M Nemer
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

Review 10.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

View more
  16 in total

1.  Enhancement of the dense-core vesicle secretory cycle by glucocorticoid differentiation of PC12 cells: characteristics of rapid exocytosis and endocytosis.

Authors:  A Elhamdani; M E Brown; C R Artalejo; H C Palfrey
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

Review 2.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

3.  Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway.

Authors:  N L Eskeland; A Zhou; T Q Dinh; H Wu; R J Parmer; R E Mains; D T O'Connor
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

4.  Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).

Authors:  L Taupenot; S K Mahata; H Wu; D T O'Connor
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

5.  Induction of interleukin-6 by depolarization of neurons.

Authors:  S Sallmann; E Jüttler; S Prinz; N Petersen; U Knopf; T Weiser; M Schwaninger
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

6.  Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.

Authors:  Nitish R Mahapatra; Daniel T O'Connor; Sucheta M Vaingankar; Amiya P Sinha Hikim; Manjula Mahata; Saugata Ray; Eugenie Staite; Hongjiang Wu; Yusu Gu; Nancy Dalton; Brian P Kennedy; Michael G Ziegler; John Ross; Sushil K Mahata
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

7.  Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.

Authors:  Rafael Molina; Elias Alvarez; Angeles Aniel-Quiroga; Maria Borque; Belen Candás; Antonio Leon; Rafael M Poyatos; Montserrat Gelabert
Journal:  Tumour Biol       Date:  2010-08-21

8.  A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A.

Authors:  H Wu; S K Mahata; M Mahata; N J Webster; R J Parmer; D T O'Connor
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Forkhead box A3 mediates glucocorticoid receptor function in adipose tissue.

Authors:  Xinran Ma; Lingyan Xu; Elisabetta Mueller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-08       Impact factor: 11.205

10.  Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure.

Authors:  Y Chen; F Rao; J L Rodriguez-Flores; N R Mahapatra; M Mahata; G Wen; R M Salem; P-A B Shih; M Das; N J Schork; M G Ziegler; B A Hamilton; S K Mahata; D T O'Connor
Journal:  Kidney Int       Date:  2008-04-23       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.